Trial Profile
Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Prasugrel; Ticagrelor
- Indications Myocardial infarction
- Focus Pharmacodynamics
- 11 Sep 2017 Status changed from not yet recruiting to recruiting.
- 17 Jan 2017 New trial record